Pateclizumab

Pateclizumab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 13636370518
Email: shyysw007@163.com
Products Intro: Product Name:Pateclizumab (anti-TNFb)
CAS:1202526-59-7
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13690
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Pateclizumab
CAS:1202526-59-7
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Pateclizumab
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Pateclizumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Products Intro: Product Name:Pateclizumab
CAS:1202526-59-7
Purity:96.96% (SEC-HPLC) Package:1mg/RMB 2656;5mg/RMB 5843;10mg/RMB 8765
Pateclizumab Basic information
Product Name:Pateclizumab
Synonyms:Pateclizumab;Research Grade Pateclizumab;Pateclizumab (anti-TNFb)
CAS:1202526-59-7
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Pateclizumab Structure
Pateclizumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Pateclizumab Usage And Synthesis
UsesPateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis[1].
References[1] Brinda Emu, et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. DOI:10.1186/ar3554
Pateclizumab Preparation Products And Raw materials
Tag:Pateclizumab(1202526-59-7) Related Product Information
Vesencumab Benufutamab Bectumomab Research Grade Vandortuzumab (DHJ76001) Mavezelimab Ivonescimab Bleselumab Vepalimomab Atoltivimab Lirentelimab